These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30927214)

  • 1. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
    Cerutti ML; Pesce A; Bès C; Seigelchifer M
    BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
    Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
    BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Control Laboratory Assessment of Quality of Rituximab Biosimilars in India.
    Mishra NN; Sharma A; Shalini S; Sharma S; Jain P; Sharma RK; Chander H; Prasad JP; Anvikar AR; Chand S
    Monoclon Antib Immunodiagn Immunother; 2022 Oct; 41(5):260-274. PubMed ID: 36306517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
    Lee KH; Lee J; Bae JS; Kim YJ; Kang HA; Kim SH; Lee SJ; Lim KJ; Lee JW; Jung SK; Chang SJ
    MAbs; 2018 Apr; 10(3):380-396. PubMed ID: 29469653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP
    Jeong YR; Jeong RU; Son JH; Kwon JC; Jung S; Song MA; Hwang JA; Lee GM
    BioDrugs; 2018 Apr; 32(2):153-168. PubMed ID: 29556960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.
    Cuello HA; Segatori VI; Alberto M; Pesce A; Alonso DF; Gabri MR
    BioDrugs; 2016 Jun; 30(3):225-31. PubMed ID: 27053342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab.
    Liu J; Eris T; Li C; Cao S; Kuhns S
    BioDrugs; 2016 Aug; 30(4):321-38. PubMed ID: 27461107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product.
    Singh SK; Pokalwar S; Bose S; Gupta S; Almal S; Ranbhor RS
    Biologics; 2018; 12():159-170. PubMed ID: 30538425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing analytical comparability of biosimilars: GCSF as a case study.
    Nupur N; Singh SK; Narula G; Rathore AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():165-171. PubMed ID: 27289250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
    Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
    MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SpeB proteolysis with imaged capillary isoelectric focusing for the characterization of domain-specific charge heterogeneities of reference and biosimilar Rituximab.
    Zhang Z; Perrault R; Zhao Y; Ding J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1020():148-57. PubMed ID: 27038651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.
    Schreiber S; Yamamoto K; Muniz R; Iwura T
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00604. PubMed ID: 32500668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
    Candelaria M; Gonzalez D; Fernández Gómez FJ; Paravisini A; Del Campo García A; Pérez L; Miguel-Lillo B; Millán S
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):515-527. PubMed ID: 29362903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.
    Xu Y; Xie L; Zhang E; Gao W; Wang L; Cao Y; Xie MH; Jiang W; Liu S
    MAbs; 2019 Apr; 11(3):606-620. PubMed ID: 30794092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous Monitoring of Monoclonal Antibody Variants by Strong Cation-Exchange Chromatography Hyphenated to Mass Spectrometry to Assess Quality Attributes of Rituximab-Based Biotherapeutics.
    Di Marco F; Berger T; Esser-Skala W; Rapp E; Regl C; Huber CG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method.
    Kim H; Hong E; Lee J; Hong S; Kim J; Cho M; Kim Y; Yoo T
    BioDrugs; 2023 Jul; 37(4):569-581. PubMed ID: 37060541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
    Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
    MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
    Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
    MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization.
    Miranda-Hernández MP; López-Morales CA; Piña-Lara N; Perdomo-Abúndez FC; Pérez NO; Revilla-Beltri J; Molina-Pérez A; Estrada-Marín L; Flores-Ortiz LF; Ruiz-Argüelles A; Medina-Rivero E
    Biomed Res Int; 2015; 2015():874916. PubMed ID: 26682224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.